Learn More
Apexbio Technology LLC LY2228820 862507-23-1 10mM (in 1mL DMSO)

Supplier: Apexbio Technology LLC A55665.1
LY2228820 (CAS 862507-23-1) is a potent selective ATP-competitive small-molecule inhibitor targeting the and isoforms of p38 mitogen-activated protein kinase (MAPK) with reported IC50 values of 5 3 nM and 3 2 nM respectively By suppressing p38 MAPK signaling LY2228820 decreases phosphorylation of heat shock protein 27 (HSP27) induced by Bortezomib thereby elevating cytotoxic effects in multiple myeloma (MM) models Additionally it inhibits secretion of IL-6 by bone marrow mononuclear cells and stromal cells as well as secretion of MIP-1 by patient-derived MM cell subsets and osteoclast precursors In melanoma (B16-F10) and NSCLC (A549) xenograft murine models LY2228820 reduces phosphorylation of MK2 and slows tumor progression respectively highlighting its potential utility in oncology research
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.